Cancer discovery could help revitalize nontoxic treatment

by



[ad_1]

Researchers at the University of Virginia have published a new study that may revitalize once promising treatments that help fight solid cancerous tumors, the university said Monday. Chief researcher Jogender Tushir-Singh, from the Department of Biochemistry and Molecular Genetics of UVA School Medicine, says the new findings could help restart human trials after further success in laboratory models. Far away, protein researchers and engineers around the world, including our research group, have focused on the super-charged and overactivating tumor cell death receptor targeting antibodies in the fight against cancer, ”Tushir said -Singh. has taken a holistic approach to harness the power of the immune system to create dual-specific and potentially clinically effective oncology therapies for solid tumors. “

“Our results also have significant potential to further improve the clinical efficacy of the antibodies targeting PD-L1 currently approved by the FDA in solid tumors, particularly those approved for fatal triple negative breast cancer,” Tushir-Singh added. . which selectively uses antibodies to target the surface of cancer cells called the death receptor-5 (DR5). The treatment has been successful in clinical trials in the past, effectively reducing tumor size in animal trials. However, when the treatment reached human clinical trials, “these antibodies have consistently failed to improve patient survival.” the university explained in a statement, allowing cancer cells to bypass treatment and continue to grow.

The research shares findings that could restore the effectiveness of treatment by fighting the biological process, which has so far been successful in shrinking tumors and improving survival in laboratory mice. “We would like to see these strategies in clinical trials, which we strongly believe have enormous potential in solid tumors,” Tushir-Singh said. “Our results are extraordinary: in addition to the translational impact, our work also explains, after more than 60 years of research in the field, why most of the approaches targeting apoptosis [cell death] did not perform well in clinical trials and eventually developed resistance to the therapies. “



[ad_2]

Source link